Helicobacter pylori

Paul Auwaerter, M.D.

Helicobacter pylori is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please log in or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

A COVID-19 Conversation - Variants, Vaccines, and Long-Term Effects

Coronavirus COVID-19 (SARS-CoV-2)

Suicide Risk in the COVID-19 Pandemic

Moderna COVID-19 Vaccine

BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)

Managing Stress and Coping with COVID-19

Johnson & Johnson COVID-19 Vaccine

-- The first section of this topic is shown below --

PATHOGENS

Helicobacter pylori: attaches to gastric cells inducing inflammation and cytokine production.
Antimicrobial effects:
- H. pylori is intrinsically resistant to sulfonamides, trimethoprim and vancomycin.
- Metronidazole resistance estimated 22-39%, 37% commonly cited in U.S. populations.
- Clarithromycin resistance ~11-12%, in some studies up to 24%.
- Amoxicillin or tetracycline resistance remains less common.

-- To view the remaining sections of this topic, please log in or purchase a subscription --

PATHOGENS

Helicobacter pylori: attaches to gastric cells inducing inflammation and cytokine production.
Antimicrobial effects:
- H. pylori is intrinsically resistant to sulfonamides, trimethoprim and vancomycin.
- Metronidazole resistance estimated 22-39%, 37% commonly cited in U.S. populations.
- Clarithromycin resistance ~11-12%, in some studies up to 24%.
- Amoxicillin or tetracycline resistance remains less common.

There's more to see -- the rest of this entry is available only to subscribers.